JAK inhibitors plus standard of care vs placebo or usual careSerious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection1 finding from 1 reviewJanus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 2901 participantsModerate